Biovaxys Technology Corp
(MENAFN- Baystreet) 11:47 AM EST - BioVaxys Technology Corp : Announced today that the Company and Horizon Technology Finance Corporation have executed a supplemental Amendment to the Asset Purchase Agreement dated February 11th, 2024 for acquiring the entire portfolio of assets and intellectual property based on the DPXTM immune educating platform technology developed by Canadian biotechnology company, IMV Inc. BioVaxys Technology Corp
shares C are trading unchanged at $0.29.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Alt.Town Introduces $TOWN Token Utility Across Platform Services And Launches Valuefi Deposit Event
- BTCC Exchange Maintains 143% Total Reserve Ratio In September 2025 Demonstrating Continued Financial Strength
- Salvium Solves The Privacy Paradox: Salvium One Delivers Mica-Compliant Privacy That Exchanges Can List
- Zebu Live 2025 Welcomes Coinbase, Solana, And Other Leaders Together For UK's Biggest Web3 Summit
- Tapbit At TOKEN2049: Reshaping The Crypto Landscape Through Product Innovation
- Thrivestate Launches“Fly Before You Buy” Program, Enabling International Buyers To Explore Dubai Before Committing
More Story
Comments
No comment